Evidence map›Paper›PMID 38779869›Full record

ArticleActa oncologica (Stockholm, Sweden)2024

Agent orange exposure and prostate cancer risk in the million veteran program.

Meghana S Pagadala, Asona J Lui, Allison Y Zhong, Julie A Lynch, Roshan Karunamuni, Kyung Min Lee, Anna Plym, Brent S Rose, Hannah K Carter, Adam S Kibel and 5 more

Abstract read
In one paragraph

Article in Acta oncologica (Stockholm, Sweden), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Comprehensive Genomic Profiles of Melanoma in Veterans Compared to Reference Databases.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025
    Article
  6. Agent Orange and head and neck cancer: A systematic review and meta-analysis.World journal of otorhinolaryngology - head and neck surgery · 2025
    Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Meghana S Pagadala *Research Service, VA San Diego Healthcare System, San Diego, CA, USA; Medical Scientist Training Program, University of California San Diego, La Jolla, CA, USA; Biomedical Science Program, University of California San Diego, La Jolla, CA, USA.
Asona J Lui *Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA.
Allison Y ZhongDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA.
Julie A LynchVA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT, USA; Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, UT, USA.
Roshan KarunamuniDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA.
Kyung Min LeeVA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT, USA; Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, UT, USA.
Anna PlymDivision of Urology, Brigham and Women's Hospital, Boston, MA, USA; Epidemiology, TH Chan School of Public Health, Harvard University, Boston, MA, USA; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Brent S RoseResearch Service, VA San Diego Healthcare System, San Diego, CA, USA; Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA.
Hannah K CarterDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Adam S KibelDivision of Urology, Brigham and Women's Hospital, Boston, MA, USA.
Scott L DuVallVA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT, USA; Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, UT, USA.
J Michael GazianoMassachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Matthew S PanizzonResearch Service, VA San Diego Healthcare System, San Diego, CA, USA; Center for Behavioral Genetics of Aging, University of California San Diego, La Jolla, CA, USA.
Richard L HaugerResearch Service, VA San Diego Healthcare System, San Diego, CA, USA; Center for Behavioral Genetics of Aging, University of California San Diego, La Jolla, CA, USA; Center of Excellence for Stress and Mental Health (CESAMH), VA San Diego Healthcare System, San Diego, CA, USA.
Tyler M SeibertResearch Service, VA San Diego Healthcare System, San Diego, CA, USA; Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA; Department of Radiology, University of California San Diego, La Jolla, CA, USA; Department of Bioengineering, University of California San Diego, La Jolla, CA, USA. tseibert@ucsd.edu.

Funding

The VETSA Longitudinal Twin Study of Cognition and Aging (VETSA 4)R01AG050595 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ELMAN, JEREMY A, FRANZ, CAROL ELAINE · 2015 to 2024
$28.0M
Predoctoral and Postdoctoral Training in Cancer Cell BiologyT32CA067754 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEAN Y.J. WANG · 1995 to 2026
$6.5M
Improving assessment of prostate cancer bone metastases using advanced diffusion imagingK08EB026503 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SEIBERT, TYLER MICHAEL · 2019 to 2022
$805k
Germline Determinants of the Breast Cancer Immune MicroenvironmentF30CA247168 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PAGADALA, MEGHANA S. · 2020 to 2023
$170k
Clinical Manipulation of Testosterone and Its Impact on Dementia and HealthI01CX001727 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI HAUGER, RICHARD L · 2019 to 2023
–
CSRD VA I01 CX001727NCI NIH HHS F30 CA247168NCI NIH HHS T32 CA067754NIA NIH HHS R01 AG050595NIBIB NIH HHS K08 EB026503
6 · The paper itself

Abstract

backgroundThe US government considers veterans to have been exposed to Agent Orange if they served in Vietnam while the carcinogen was in use, and these veterans are often deemed at high risk of prostate cancer (PCa). Here, we assess whether presumed Agent Orange exposure is independently associated with increased risk of any metastatic or fatal PCa in a diverse Veteran cohort still alive in the modern era (at least 2011), when accounting for race/ethnicity, family history, and genetic risk. PATIENTS AND

methodsParticipants in the Million Veteran Program (MVP; enrollment began in 2011) who were on active duty during the Vietnam War era (August 1964-April 1975) were included (n = 301,470). Agent Orange exposure was determined using the US government definition. Genetic risk was assessed via a validated polygenic hazard score. Associations with age at diagnosis of any PCa, metastatic PCa, and death from PCa were assessed via Cox proportional hazards models. RESULTS AND

interpretationOn univariable analysis, exposure to Agent Orange was not associated with increased PCa (hazard ratio [HR]: 1.02, 95% confidence interval [CI]: 1.00-1.04, p = 0.06), metastatic PCa (HR: 0.98, 95% CI: 0.91-1.05, p = 0.55), or fatal PCa (HR: 0.94, 95% CI: 0.79-1.09, p = 0.41). When accounting for race/ethnicity and family history, Agent Orange exposure was independently associated with slightly increased risk of PCa (HR: 1.06, 95% CI: 1.04-1.09, <10-6) but not with metastatic PCa (HR: 1.07, 95% CI: 0.98-1.15, p = 0.10) or PCa death (HR: 1.02, 95% CI: 0.83-1.23, p = 0.09). Similar results were found when accounting for genetic risk. Agent Orange exposure history may not improve modern PCa risk stratification.

Indexed as

Agent OrangeProstatic NeoplasmsVeteransVietnam Conflict2,4,5-Trichlorophenoxyacetic Acid2,4-Dichlorophenoxyacetic AcidAgedDefoliants, ChemicalHumansMaleMiddle AgedPolychlorinated DibenzodioxinsRisk FactorsUnited States2,4,5-Trichlorophenoxyacetic Acid2,4-Dichlorophenoxyacetic AcidAgent OrangeDefoliants, ChemicalPolychlorinated Dibenzodioxins

Identifiers

PMID38779869
PMCPMC11332552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.